TrialThe oncologist2018

Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.

Hisato Kawakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.